Published in Int J Infect Dis on May 16, 2013
Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease | NCT01680822
Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLoS One (2014) 1.37
Management of nontuberculous mycobacterial infection in the elderly. Eur J Intern Med (2014) 1.04
Molecular epidemiology of nontuberculous mycobacteria isolates from clinical and environmental sources of a metropolitan city. PLoS One (2014) 1.01
Highlight on advances in nontuberculous mycobacterial disease in North America. Biomed Res Int (2014) 0.94
Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt) (2014) 0.91
The Challenge of Pulmonary Nontuberculous Mycobacterial Infection. Curr Pulmonol Rep (2015) 0.84
Nontuberculous Mycobacteria: Epidemiologic, Mycobacteriologic, and Clinical Aspects. Biomed Res Int (2015) 0.82
'"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection. BMC Med (2016) 0.82
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis. Biomed Res Int (2015) 0.82
Clinical findings in relation to mortality in non-tuberculous mycobacterial infections: patients with Mycobacterium avium complex have better survival than patients with other mycobacteria. Eur J Clin Microbiol Infect Dis (2015) 0.81
Prevalence and factors associated with nontuberculous mycobacteria in non-cystic fibrosis bronchiectasis: a multicenter observational study. BMC Infect Dis (2016) 0.78
Infections in "noninfectious" lung diseases. Ann Am Thorac Soc (2014) 0.78
Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis. Int J Mycobacteriol (2015) 0.77
Immunomodulatory effect of macrolides: At what cost? Respir Med Case Rep (2016) 0.75
How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Blood (2016) 0.75
Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis. Int J Mol Sci (2016) 0.75
Global impact of bronchiectasis and cystic fibrosis. Breathe (Sheff) (2016) 0.75
Suspecting non-cystic fibrosis bronchiectasis: What the busy primary care clinician needs to know. Int J Clin Pract (2017) 0.75
Latin America validation of FACED score in patients with bronchiectasis: an analysis of six cohorts. BMC Pulm Med (2017) 0.75
Body habitus in patients with and without bronchiectasis and non-tuberculous mycobacteria. PLoS One (2017) 0.75
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med (1997) 8.10
Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med (2008) 4.33
Bronchiectasis. N Engl J Med (2002) 2.91
Non-cystic fibrosis bronchiectasis. J R Coll Physicians Edinb (2011) 2.76
Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur Respir J (2004) 2.28
Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest (2006) 2.04
Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. Chest (1999) 1.80
Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings. Radiology (2004) 1.78
Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology (2005) 1.66
Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J (2008) 1.31
Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol (2005) 1.30
Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med (1997) 1.25
Non-tuberculous mycobacteria in patients with bronchiectasis. Thorax (2005) 1.23
Effect of oestrogen on Mycobacterium avium complex pulmonary infection in mice. Clin Exp Immunol (2001) 1.18
Postmenopausal changes in serum cytokine levels and hormone replacement therapy. Am J Obstet Gynecol (2001) 1.05
Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients. J Clin Microbiol (2011) 1.04
Sex differences in host resistance to Mycobacterium marinum infection in mice. Infect Immun (1991) 1.03
Use and evaluation of molecular diagnostics for pneumonia etiology studies. Clin Infect Dis (2012) 1.00
Investigation of mycobacterial colonisation and invasion of the respiratory mucosa. Thorax (2003) 0.90
Interaction between mycobacteria and mucus on a human respiratory tissue organ culture model with an air interface. Exp Lung Res (2004) 0.84
Bronchiectasis and non-tuberculous mycobacterial pulmonary infection. Thorax (2006) 0.79
Mycobacterial infection associated with the use of an anabolic steroid. Med J Aust (1993) 0.78
Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol (2006) 2.96
Macrophages are necessary for maximal nuclear factor-kappa B activation in response to endotoxin. Am J Respir Cell Mol Biol (2002) 2.05
A woman in her 40s with AIDS and lung mass. Chest (2014) 1.99
Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res (2008) 1.22
Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. J Virol (2005) 1.16
FoxM1 mediates the progenitor function of type II epithelial cells in repairing alveolar injury induced by Pseudomonas aeruginosa. J Exp Med (2011) 1.14
Intratracheal administration of liposomal clodronate accelerates alveolar macrophage reconstitution following fetal liver transplantation. J Leukoc Biol (2004) 1.11
TREM-1 expression in macrophages is regulated at transcriptional level by NF-kappaB and PU.1. Eur J Immunol (2007) 1.07
Dangkwisoo-san, an herbal medicinal formula, ameliorates acute lung inflammation via activation of Nrf2 and suppression of NF-κB. J Ethnopharmacol (2012) 1.04
Functional PU.1 in macrophages has a pivotal role in NF-κB activation and neutrophilic lung inflammation during endotoxemia. Blood (2011) 1.03
Induction and function of lipocalin prostaglandin D synthase in host immunity. J Immunol (2007) 1.01
Bioluminescent detection of endotoxin effects on HIV-1 LTR-driven transcription in vivo. J Histochem Cytochem (2003) 0.99
Idiopathic pulmonary artery dissection: a case report. J Med Case Rep (2009) 0.98
MYD88-dependent and -independent activation of TREM-1 via specific TLR ligands. Eur J Immunol (2010) 0.98
PGD synthase and PGD2 in immune resposne. Mediators Inflamm (2012) 0.95
A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Pharm Res (2010) 0.92
Lipopolysaccharide-dependent interaction between PU.1 and c-Jun determines production of lipocalin-type prostaglandin D synthase and prostaglandin D2 in macrophages. Am J Physiol Lung Cell Mol Physiol (2009) 0.88
Yin Yang 1 enhances cyclooxygenase-2 gene expression in macrophages. Am J Physiol Lung Cell Mol Physiol (2007) 0.88
Lung cancer mimicking as pregnancy with pneumonia. Lung Cancer (2008) 0.88
Protective Effect of the Fruit Hull of Gleditsia sinensis on LPS-Induced Acute Lung Injury Is Associated with Nrf2 Activation. Evid Based Complement Alternat Med (2012) 0.87
Role of nicotinamide adenine dinucleotide phosphate-reduced oxidase proteins in Pseudomonas aeruginosa-induced lung inflammation and permeability. Am J Respir Cell Mol Biol (2013) 0.87
Adrenal insufficiency as a presenting manifestation of nonsmall cell lung cancer. South Med J (2009) 0.85
NF-kappaB-inducing kinase regulates cyclooxygenase 2 gene expression in macrophages by phosphorylation of PU.1. J Immunol (2007) 0.85
Curcumin mediated epigenetic modulation inhibits TREM-1 expression in response to lipopolysaccharide. Int J Biochem Cell Biol (2012) 0.84
Endovascular therapy yields significantly superior outcomes for large vessel occlusions compared with intravenous thrombolysis: is it time to randomize? J Neurointerv Surg (2012) 0.84
Use of bioluminescent imaging to investigate the role of nuclear factor-kappaBeta in experimental non-small cell lung cancer metastasis. Clin Exp Metastasis (2007) 0.84
Regulation of cyclooxygenase-2 expression by small GTPase Rac2 in bone marrow macrophages. Am J Physiol Lung Cell Mol Physiol (2007) 0.84
Lipopolysaccharide-induced expression of microsomal prostaglandin E synthase-1 mediates late-phase PGE2 production in bone marrow derived macrophages. PLoS One (2012) 0.83
Therapeutic Effect of the Tuber of Alisma orientale on Lipopolysaccharide-Induced Acute Lung Injury. Evid Based Complement Alternat Med (2013) 0.83
ent-kaur-16-en-19-oic Acid, isolated from the roots of Aralia continentalis, induces activation of Nrf2. J Ethnopharmacol (2011) 0.83
Curcumin and lung cancer--a review. Target Oncol (2014) 0.83
Opioid effect on lungs. Respirology (2013) 0.82
Achromobacter respiratory infections. Ann Am Thorac Soc (2015) 0.82
Induction of cyclooxygenase-2 signaling by Stomatococcus mucilaginosus highlights the pathogenic potential of an oral commensal. J Immunol (2013) 0.81
Nrf2 is essential for the expression of lipocalin-prostaglandin D synthase induced by prostaglandin D2. Free Radic Biol Med (2013) 0.80
MyD88 is a mediator for the activation of Nrf2. Biochem Biophys Res Commun (2010) 0.79
Inhibitory kappaB kinase 2 activates airway epithelial cells to stimulate bone marrow macrophages. Am J Respir Cell Mol Biol (2007) 0.78
Genetic determination of the role of PU.1 in macrophage gene expression. Biochem Biophys Res Commun (2008) 0.78
Polymyxin B self-associated with phospholipid nanomicelles. Pharm Dev Technol (2011) 0.78
Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis. Int J Mycobacteriol (2015) 0.77
A 62-year-old female patient with left-sided pleural effusion. Expert Rev Respir Med (2013) 0.76
Response. Chest (2014) 0.75
Cryptococcal endocarditis. South Med J (2011) 0.75
Cutaneous precursor B-cell lymphoblastic lymphoma in association with Epstein-Barr virus. Am J Dermatopathol (2011) 0.75
Respiratory failure due to blastomycosis infection in a patient with hypertension, cirrhosis and chronic pancreatitis. Expert Rev Respir Med (2013) 0.75
Pulmonary artery dissection and rupture in a patient with idiopathic pulmonary artery hypertension. Am J Respir Crit Care Med (2014) 0.75
Repeated Ramp Tests on Stable LVAD Patients Reveal Patient-Specific Hemodynamic Fingerprint. ASAIO J (2017) 0.75
Dimensions of the posterior cerebral circulation: an analysis based on advanced non-invasive imaging. J Neurointerv Surg (2012) 0.75
HVAD Waveform Analysis as a Noninvasive Marker of Pulmonary Capillary Wedge Pressure: A First Step Toward the Development of a Smart Left Ventricular Assist Device Pump. ASAIO J (2017) 0.75